Outcome of the Board Meeting
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals) has released its audited financial results for Q4 and full year ended March 31, 2026. On a standalone basis, revenue declined to ₹2,030.50 Cr from ₹2,504.43 Cr in the previous year, while net profit fell to ₹228.71 Cr from ₹491.18 Cr. Consolidated revenue stood at ₹2,268.55 Cr versus ₹2,608.50 Cr, with consolidated net profit at ₹150.12 Cr compared to ₹484.24 Cr. The significant declines are partly attributable to the merger with erstwhile Cohance Lifesciences Limited (approved by NCLT in March 2025, effective May 2025), with prior period figures restated. The auditors issued an unmodified opinion with an emphasis of matter on the merger accounting. Exceptional items totaling ₹29.47 Cr include a ₹16.51 Cr customer settlement claim, restructuring costs, and labor code implementation expenses.
The company has experienced substantial declines in both revenue and profitability, largely due to the merger-related costs and a ₹16.51 Cr one-time customer settlement. However, the clean audit opinion and completed merger may provide stability going forward.